1. Treatment of non-muscle invasive bladder cancer with Bacillus Calmette–Guerin (BCG): Biological markers and simulation studies
   Alex Kiselyov et al, 2015, BBA Clinical CrossRef
2. Urinary Protein Markers for the Detection and Prognostication of Urothelial Carcinoma
   Tibor Szarvas et al, 2018, Urothelial Carcinoma CrossRef
3. Prognostic Role of Tenascin-C for Cancer Outcome: A Meta-Analysis
   Xinliang Ming et al, 2019, Technology in Cancer Research & Treatment CrossRef
4. Promotion effects of acetoaceto-o-toluidide on N-butyl-N-(4-hydroxybutyl)nitrosamine-induced bladder carcinogenesis in rats
   Nao Yukimatsu et al, 2019, Archives of Toxicology CrossRef
5. Association between interleukin-22 genetic polymorphisms and bladder cancer risk
   Tao Zhao et al, 2015, Clinics CrossRef
6. Matricellular proteins in drug delivery: Therapeutic targets, active agents, and therapeutic localization
   Andrew J. Sawyer et al, 2016, Advanced Drug Delivery Reviews CrossRef
7. A Systematic Review of the Diagnostic and Prognostic Value of Urinary Protein Biomarkers in Urothelial Bladder Cancer
   Jamie J. D’Costa et al, 2016, Bladder Cancer CrossRef
8. The cancer‐associated fibroblasts related gene CALD1 is a prognostic biomarker and correlated with immune infiltration in bladder cancer
   YiHeng Du et al, 2021, Cancer Cell International CrossRef
9. The Matrix Revolution: Matricellular Proteins and Restructuring of the Cancer Microenvironment
   Casimiro Gerarduzzi et al, 2020, Cancer Research CrossRef
10. Tenascin-C promotes bladder cancer progression and its action depends on syndecan-4 and involves NF-κB signaling activation
    Zhenfeng Guan et al, 2022, BMC Cancer CrossRef